This is to inform that the Board of Directors of the Company at its meeting held on May 19, 2026, has, inter alia, considered and approved the Audited Financial Results of the Company (Standalone and Consolidated), Cash Flow Statement, Statement of Assets and Liabilities together with the Audit Report thereon for the quarter and year ended March 31, 2026.
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.3 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
HCG reported FY26 standalone revenue of Rs 1,35,937 lakhs, up 6.5% from Rs 1,27,652 lakhs in FY25. However, profit after tax declined 9.2% to Rs 1,458 lakhs from Rs 1,605 lakhs, impacted by exceptional items totaling Rs 5,538 lakhs including Rs 3,752 lakhs impairment on BACC Healthcare divestment, Rs 3,000 lakhs impairment on Kolkata subsidiary, partly offset by Rs 2,000 lakhs reversal on Manavata Oncology. The company completed a Rs 42,059 lakhs rights issue in March 2026 and approved divestment of fertility business BACC to Inviga Healthcare Fund I for Rs 3,764 lakhs (classified as related party transaction). Auditors BSR & Co issued unqualified opinion.
Despite revenue growth, heavy impairment charges dragged PAT lower. The BACC divestment removes a non-core business. Rights issue proceeds of Rs 42,059 lakhs remain unutilised pending deployment. Shareholders should note the PAT decline and significant one-time exceptional items affecting FY26 earnings.